Health technologies have value if and only if they are used -- or, as we wrote in Millions Saved after reviewing 17 large-scale successes in global health, what's needed is "innovation within an effective delivery system, at a sustainable price." That simple observation bears repeating as a caravan of new drugs, diagnostic products and vaccines for diseases that predominantly affect poor countries move through the R&D pathway, and yet face speed bumps when it's time for scaled-up manufacture and d
CGD Policy Blogs
Peter Huber of the Manhattan Institute's Center for Legal Policy has just published a great overview of the economic rationale for the widely unpopular practices of the pharmaceutical industry, aptly titled "Of Pills and Profits: In Defense of Big Pharma." He argues:
From the foundation's press release:
The Bill & Melinda Gates Foundation today announced 16 grants totaling $287 million to create an international network of highly collaborative research consortia focused on accelerating the pace of HIV vaccine development.
The grants will support a range of innovative approaches for designing an effective HIV vaccine, and bring together more than 165 investigators from 19 countries to tackle some of the biggest scientific challenges facing the field.
Today's Houston Chronicle
As of this year's G8 meeting, however, the Global Fund is struggling to keep its programs alive. The G8 leaders, led by the United States, should pledge to keep this innovative, efficient fund working. They should also launch another measure â€” praised by almost all leaders in foreign aid and development â€” to streamline the malaria fight further.
On Tuesday, the Chicago Tribune profiled a controversial clause of U.S. immigration law that bans admission by foreign nationals who have HIV or AIDS. In 1987, the height of the AIDS scare in this country, HIV was added to the list of "communicable diseases of public health significance," and therefore deemed sufficient grounds for denying entry under the Immigration and Naturalization Act.
Esther Duflo and Michael Kremer, writing in today's LibÃ©ration (a sister paper of the FT, published in French), discuss the prospects for an agreement at this weekend's G8 meeting on proposals for an Advance Market Commitment for new vaccines and for an airline solidarity tax.
Here is an unofficial translation from French of the article's conclusion: